ALPHARETTA, Ga., Nov. 8, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in a fireside chat at the UBS 2024 Healthcare Conference on Tues., Nov. 12 at approximately 2:45 p.m. Pacific Time.
A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.
About Avanos Medical, Inc.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit Avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
| Last Trade: | US$12.03 |
| Daily Change: | -0.38 -3.06 |
| Daily Volume: | 361,052 |
| Market Cap: | US$552.900M |
February 26, 2025 November 12, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
